Regenxbio (RGNX) Free Cash Flow (2014 - 2025)

Regenxbio's Free Cash Flow history runs 12 years deep, the most recent figure standing at -$54.4 million for Q4 2025.

• On a quarterly basis, Free Cash Flow fell 73.96% year-over-year to -$54.4 million in Q4 2025; TTM through Dec 2025 was -$126.4 million, a 26.66% increase from a year earlier, with the FY2025 full-year figure at -$126.4 million, up 26.66% from the prior year.
• Free Cash Flow advanced to -$54.4 million in Q4 2025 per RGNX's latest filing, from -$58.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $408.8 million in Q4 2021 and bottomed at -$109.7 million in Q3 2021.
• The 5-year median for Free Cash Flow is -$47.0 million (2021), against an average of -$25.3 million.
• Biggest YoY gain for Free Cash Flow was 3523.67% in 2021; the steepest drop was 302.63% in 2021.
• Year by year, Free Cash Flow stood at $408.8 million in 2021, then slumped by 109.15% to -$37.4 million in 2022, then climbed by 18.93% to -$30.3 million in 2023, then fell by 3.15% to -$31.3 million in 2024, then tumbled by 73.96% to -$54.4 million in 2025.
• Per Business Quant, the three latest RGNX Free Cash Flow figures stand at -$54.4 million (Q4 2025), -$58.3 million (Q3 2025), and -$46.2 million (Q2 2025).